Telix Pharmaceuticals
- Market cap
- 3.77B
- P/E (TTM)i
- 114.64
- P/Bi
- 9.07
- EPSi
- -0.02
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- Total institutional ownership rose 0.9 percentage points.
Institutional ownership
- Held by institutions
- 48.52% +0.93pp
- Institutions
- 141
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-07-21
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
17 filings tracked · 3 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| Christian Behrenbruch | Co-Founder, MD, Group CEO & Executive Director | 6.41% |
| Mark Nelson | Independent Non-Executive Director | 1.07% |
| Jann Skinner | Independent Non-Executive Director | 0.18% |
| David Cade | Chief Executive Officer of Asia Pacific | 0.11% |
| Darren Patti | Chief Operating Officer of Americas | 0.01% |
| Darren Smith | Group Chief Financial Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-06 | Darren Smith | Group Chief Financial Officer | Private Acquisition | +2,071 | $9.66 |
| 2026-04-28 | Christian Behrenbruch | Co-Founder, MD, Group CEO & Executive Director | Open Market Acquisition | +67,935 | $14.48–14.87 |
| 2026-03-28 | Darren Smith | Group Chief Financial Officer | Derivative Exercise and Retained | +1,111 | -- |
| 2026-03-17 | David Cade | Chief Executive Officer of Asia Pacific | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Darren Smith | Group Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Mark Nelson | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Christian Behrenbruch | Co-Founder, MD, Group CEO & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jann Skinner | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Darren Patti | Chief Operating Officer of Americas | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:11:57 · For reference only, not investment advice and not tailored to your situation.